Replies to post #32646 on RespireRx Pharmaceuticals Inc (fka RSPI)

[DewDiligence]

Good point on the combination product called Valturna (#msg-41609619), which might suffer a modest setback from the failed Diovan study. However, the main reason for the slow uptake of Valturna has been that the medical community has not (yet) been sold on the benefits of the Tekturna component. Regards, Dew